Genelux (GNLX) Income from Continuing Operations (2022 - 2026)
Genelux's (GNLX) quarterly Income from Continuing Operations came in at 9334000.0 in Q1 2026, down 21.02% year-on-year from 11817652.99 in Q1 2025, and up 89.37% quarter-over-quarter from 87805000.0 in Q4 2025.
Genelux (GNLX) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Genelux's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 9334000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 21.02% year-over-year to 9334000.0 in Q1 2026; TTM through Mar 2026 was 116480000.0, a 278.33% decrease from a year earlier, with the FY2025 full-year figure at 111024000.0, down 21.05% from the prior year.
- Income from Continuing Operations grew to 9334000.0 in Q1 2026 per GNLX's latest filing, from 87805000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4909000.0 in Q3 2022 and bottomed at 117160000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 8061000.0 (2025), against an average of 19612866.67.
- Across the five-year window, Income from Continuing Operations surged 94.26% in 2024 and sank 828.27% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 3495000.0 in 2022, then sank by 93.62% to 6767000.0 in 2023, then tumbled by 39.78% to 9459000.0 in 2024, then sank by 828.27% to 87805000.0 in 2025, then soared by 89.37% to 9334000.0 in 2026.
- Per Business Quant, the three latest GNLX Income from Continuing Operations figures stand at 9334000.0 (Q1 2026), 87805000.0 (Q4 2025), and 11280000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -9.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.33 Mn |
| Dec 31, 2025 | -87.81 Mn |
| Sep 30, 2025 | -11.28 Mn |
| Jun 30, 2025 | -8.06 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Sep 30, 2024 | -6.89 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -9.50 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -117.16 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |